Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,183.6% in July

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 191,579 shares, an increase of 1,183.6% from the June 30th total of 14,925 shares. Based on an average daily volume of 394,403 shares, the short-interest ratio is presently 0.5 days. Currently, 0.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Daiichi Sankyo has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

Shares of Daiichi Sankyo stock traded up $0.24 during mid-day trading on Friday, reaching $17.25. 146,211 shares of the stock traded hands, compared to its average volume of 397,992. The stock has a market capitalization of $32.13 billion, a PE ratio of 18.35, a PEG ratio of 2.97 and a beta of -0.17. The business has a 50-day moving average of $16.40 and a 200 day moving average of $17.91. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $27.50. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, analysts predict that Daiichi Sankyo will post 0.96 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.